Prime Medicine PRME Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -216.1%-69.3pp | -146.8%-34.5pp | -112.3%+42.5pp | -154.8%-39.6pp | -115.2%+21.7pp | |
| Return on assets | -63.7%-0.9pp | -62.8%-7.8pp | -55%+19.0pp | -74%-10.8pp | -63.2%+16.6pp | |
| Liquidity | ||||||
| Current ratio | 3.8×-1.0× | 4.8×-1.8× | 6.6×+3.1× | 3.6×-1.2× | 4.8×-0.8× | |
| Quick ratio | 3.8×-1.0× | 4.8×-1.8× | 6.6×+3.1× | 3.6×-1.2× | 4.8×-0.8× | |
| Cash ratio | 2.1×+0.1× | 2×-0.4× | 2.4×+0.5× | 2×-1.1× | 3.1×-2.1× | |
| Leverage | ||||||
| Debt-to-equity | 1.5×+0.5× | 1×+0.2× | 0.7×-1.2× | 2×+0.8× | 1.1×+0.9× | |
| Debt-to-assets | 0.4×0.0× | 0.3×0.0× | 0.3×-0.1× | 0.4×+0.1× | 0.4×+0.2× | |
| Per Share | ||||||
| Book value per share | $0.43-46.7% | $0.81-19.4% | $1.01+114% | $0.47-42.3% | $0.82-36.7% | |
| Valuation | ||||||
| Market capitalization | $574.36M+111% | $626.37M-36.6% | $987.64M+248% | $283.6M+8.7% | $261.01M-31.8% | |
| Enterprise value | $611.08M+113% | $666.08M-34.7% | $1.02B+204% | $335.84M+21.6% | $276.22M+21.6% | |
| Price / book | 7.5×+4.9× | 5.2×-0.9× | 6.1×+1.4× | 4.7×+2.2× | 2.4×-0.1× | |
| Earnings yield | -34.5%+39.8pp | -32.1%-12.1pp | -20%+50.3pp | -70.3%+7.1pp | -77.4%-26.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Prime Medicine's ratios come from?
- Every ratio is computed from Prime Medicine's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
